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Abstract
The main objective of this paper is to evaluate possible socio-economic status, clinical, and
treatment associations with the occurrence of distant metastasis in Stage I – III breast cancer
patients. After analysis in a logistic regression model, four variables were found to be
significant with occurrence of distant metastases. These variables were: education, disease group
(Triple-negative, Her2Neu-positive and Luminal A), stage at diagnosis, and concordance to
chemotherapy based on the NCCN guidelines. Patients without a college degree were found to
be more likely to develop distant metastasis than those with a college degree (OR = 2.46 95% CI
1.44 – 4.23). Triple-negative and Her2Neu-positive patients had higher odds of having distant
metastasis than those in with luminal A disease (OR = 3.88 and 3.22 95% CI 2.25 – 6.69 and
1.88 – 5.52, respectively). Stage III patients also had higher odds of having distant metastasis
than those with Stage I disease (OR = 5.41 95% CI 2.74 – 10.65). Finally, an unusual result was
discovered where patients who were not classified to a chemotherapy guideline were
significantly less likely to have distant metastasis than their counterparts who received the
recommended chemotherapy (OR = .32 95% CI 0.17 - 0.58).
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1. Introduction
Cancer is a disease of growing concern in today’s world. New research is done every day in an
attempt to discover more about this disease and how it works. There is no doubt that many
questions regarding cancer are unanswered. There is a great need for research on this subject to
find out better ways to treat and cure cancer patients. This research project focuses on breast
cancer, specifically distant metastasis, and attempts to answer questions about the characteristics
a patient may have in relation to distant metastasis. A distant metastasis is defined as cancer that
has spread from the original (primary) tumor to distant organs or distant lymph nodes. In this
case, a distant metastasis would mean the cancer has spread to an area other than the breast (the
primary site).
There were two main research questions investigated in this analysis. The first was whether
triple-negative breast cancer is associated with developing a distant metastasis. The second was
whether a patient’s type of treatment is associated with developing a distant metastasis.
Typically, triple-negative patients are harder to treat because of their unique status, so it was
thought that this group might be associated with higher probability of getting a distant
metastasis. In addition, it was thought that patients who received both radiation and
chemotherapy, instead of just one or the other, might have a lower probability of developing
distant metastasis. Other variables were included in the analysis as controls and/or additional
variables of interest. These variables included information about socio-economic status, clinical,
and treatment.
The data for this analysis was based on a sample of patients from the City of Hope National
Medical Center. The data is stored in the National Comprehensive Cancer Network (NCCN)
Outcomes Database. This database consists of many different data tables, each with many
different variables within the table. Data is grouped in “raw” data sets that are just pure data as
entered into the database and also “derived” data sets that are created from the raw data using
predefined programming algorithms. All data is stored in a SQL database and downloaded into
SAS data sets that use a hierarchal data structure. Each data set has a corresponding data
dictionary which was reviewed to identify variables of interest. The focus for this analysis was a
group of patients diagnosed with stage I-III breast cancer and the objective was to choose and
test the significance of possible variables that might have an association with whether a breast
cancer patient experiences a distant metastasis, using logistic regression.
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2. Data Cleaning and the Final Data Set
A major component of this project included programming in SAS to read in data, make
necessary exclusions, obtain variables of interest, and create new variables from existing ones for
analysis. In order to make the data manageable, the data sets had to be reviewed to identify the
cohort and variables of interest. Only certain data sets were read into SAS and then merged to
create the final cohort data set.

2.1 Exclusions and Controls
In order to carry out an accurate analysis, exclusions had to be made. Some patients were
excluded right when the data was read in to SAS. This included patients who did not have
enough follow-up for an analysis that involved radiation therapy (270 days from presentation).
Some patients had second episodes of breast cancer, so observations were limited to the first
occurrence of cancer and patients with bilateral disease were also excluded. The goal was to
investigate treatment and disease group effects on metastases, so any patients with no treatment
information were to be deleted. Only patients with treatment defined as adjuvant therapy
(treatment given after the primary surgery) and neo-adjuvant therapy (treatment given prior to
the primary surgery to shrink the tumor) were included, since these treatments are given to lower
the risk of recurrence. Since the other primary goal of the analysis was to identify if disease
group is associated with distant metastasis, patients with missing or unknown estrogen or
progesterone receptor or Her2Neu status were excluded, because they would not be able to be
classified into a disease grouping.
Stage IV patients were excluded because they are a different subset of people. These patients
have metastases at diagnosis, where the stage I-III patients do not. Stage IV patients are usually
terminal and too far along in the disease to be considered in an analysis looking at predictors of
distant recurrence. Since the primary interest was in the characteristics that help predict if a
patient gets distant metastasis, it does not make sense to include Stage IV patients that have
already metastasized. Stage 0 patients were also excluded because chemotherapy, one of the
treatments of interest in this analysis, is not usually given to this group of patients. Stage 0
patients are typically treated as a preventative measure and thus did not fit in to the cohort. Out
of the 2,200 total patients in the data set, 964 fit the criteria and were included in the analysis.

2.2 SAS Programming
The first step in the programming process was to identify all variables of interest from the
various data dictionaries. Patients were excluded that did not fit the criterion as described in the
previous section. A total of 11 different data sets were used in this analysis. These data sets are
grouped in a hierarchical database model, meaning that the data is organized into a tree-like
structure and linked together by keys. All of the data sets have a common key variable, patient
ID (pid), and some share diagnosis ID (dxid) and possibly tumor ID (tumorid) key variables as
well. The patients are identified by pid and then each different diagnosis is identified by dxid
within the pid key. In addition, the tumorid key identifies different tumors within each
diagnosis. Since many of the data sets contain information on patients with recurrence or more
than one tumor, there is the possibility for more than one record per patient. In this case, these
5

records are organized by the dxid and tumorid variables within each pid. However, some of the
data sets are already narrowed down to one record per patient, like the demographics data sets.
Because of this, data sets had to be sorted and merged in a specific manner in order to get the
correct information based on one record per patient. Table 1 summarizes the variables and the
corresponding tables they were found in.
Table 1: Data Sets and Variables
Data Set
Patient Characteristics (derived)
Clinical Characteristics (derived)
Adjuvant Drug Therapy (derived)
Metastasis Patient Characteristics
(derived)
Surgical Information (derived)
Metastatic Sites (raw)
Study Accession (raw)
Insurance (raw)
Solid Tumor Stage (raw)
Treatment (raw)
Concordance (derived)

Variables
Age at Diagnosis, Income, Race,
Follow-Up Radiation Therapy Flag
Final Stage
Flags for Adjuvant Treatment
Group

Key Variables

Age at Metastasis

pid, dxid

Definitive Surgery Group
Distant Metastasis variables
Education Level, Employment
Status, Height, Weight
Insurance Provider
Radiation Flags and Disease Group
Radiation Flags and Neoadjuvant/Adjuvant Flags
Concordance Information

pid, dxid, tumorid
pid, dxid

pid
pid, dxid, tumorid
pid, dxid

pid
pid
pid, dxid, tumorid
pid, dxid
pid, dxid, tumorid

Within these data sets, code was used to manipulate and create new variables to be used in the
model. In the Adjuvant Drug Therapy data set, a binary variable was created for whether or not
a patient had chemotherapy. The Metastasis Patient Characteristics data was used to create a
variable for time to metastasis from original diagnosis. As described later, this variable was
intended for use in a subsequent analysis. The Metastatic Sites data set included variables that
were used to determine where the metastasis occurred and a variable (the response variable) was
created for whether or not a patient had distant metastasis or not. The Solid Tumor Stage data set
provided useful data for laterality of the patient’s breast cancer and for creating a categorical
variable for a patient’s disease group based on certain clinical characteristics. The raw
Treatment data set provided data to classify patients into neo-adjuvant/adjuvant radiation
treatment groupings and to ensure patients were only flagged for radiation treatment if the
treatment side was equal to the laterality of the breast cancer.
Finally, to create the most complex variables, the derived Concordance data set was used to
manipulate the concordance variables for each patient. Since it is possible for patients to be put
on several guidelines, some patients had multiple observations to account for concordance on
different guidelines. The concordance data set contained variables for concordance (Yes/No/Not
evaluated), guideline, version, and reason if the patient was not concordant. The data was
transposed to get a row for each corresponding concordance, guideline, version, and reason
variable for each patient. The data was then merged with itself to create one row per patient and
four sets of each of the four concordance variables (since any patient is on at most four
6

guidelines). The following merge creates a four columns, one for each guideline a patient may
be on. This was repeated for each of the three other variables.
**Merge data with itself to get one record per patient;
data Mconcord;
merge trconcord (where=(_NAME_='guideline') keep=pid dxid tumorid
_NAME_ col1-col4 rename=(COL1=Guideline1) rename=(COL2=Guideline2)
rename=(COL3=Guideline3)rename=(COL4=Guideline4))
...
by pid dxid tumorid;
run;

The last step in the initial programming was to combine and merge all of the relevant data sets
into one final data set with the variables of interest. Care had to be taken to combine data sets
with the set of common keys first starting at the tumor level (pid, dxid, tumorid). Then this
result could be combined with those data sets at the next level (pid and dxid), and finally
combined with those data sets that just use pid as a key. Several sets of merges with trackers
were used to accomplish this. In addition, binary variables were created at the appropriate parts
of the program to indicate if a patient had radiation treatment and/or a distant metastasis. For
example, if the patient had a missing value for metastatic site, then the patient was recorded as
having no metastasis. At the end, the final data set was reviewed to ensure there was only one
record per patient.

2.3 Predictors
Once the final patient level data set was created, an analysis data set was made. In this analysis
data set, variables were created and manipulated so that they could be used in the logistic
regression models. A body mass index (BMI) variable was created from the height and weight
data, as well as a categorical variable based on BMI. Many of the predictors, such as age, were
collapsed into interesting groups that were clinically meaningful. Breakpoints of <50 (premenopause), 50-<70 (midrange) and 70+ (older) were chosen due to their relationship with
breast cancer care at a biological and clinical level. Continuous variables were tested for
linearity in the logit and categorical variables were included if the variable met the appropriate
assumptions for the analysis. Groups for categorical variables were collapsed, defined by what
seemed to make sense and would be easy to understand and interpret. Collapsing these
categorical variables prevented convergence issues from having too few observations in any one
group. The analytic data set is also where final exclusions were made, such as patients who were
stage IV at diagnosis. Instead of deleting excluded patients, they were output to a second data
set to double check that patients were excluded for correct reasons.
In order to be able to use logistic regression, the response variable (distant metastasis) was
collapsed into two groups. One group was patients who experienced distant metastasis, and the
other was patients who experienced local metastasis or no metastasis. For ease of discussion of
the predictor variables, they were grouped into three categories/types: personal and socioeconomic status characteristics, clinical characteristics, and treatment characteristics.
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The personal and socio-economic status variables included: age at diagnosis, body mass index
(BMI), BMI group, race, insurance, education level, employment status, and income. Age at
diagnosis was tested for linearity in the logit by using a Box-Tidwell transformation, and failed.
BMI was tested for linearity in the logit using the same method, and passed. However, as stated
earlier, BMI was not significant as a continuous predictor, so it was grouped by clinically
meaningful cutoffs for underweight, normal, overweight, and obese, and then tested as a
categorical variable as well. Race was collapsed into the three largest groups: Caucasian,
Hispanic, and African American. A fourth group, “Other,” was added for those who did not fall
into any of those categories. Insurance was broken up into four groups: Managed Care,
Medicare, Medicaid, and other. Education level was collapsed into three categories: college
degree (college, some college/AA and graduate school), no college degree, and unknown/other.
Employment status was broken up into employed (including employed students), student, and
other. Table 2 provides a summary of these variables.
Table 2: Personal and Socio-Economic Status Characteristics1

Variable

Underweight
Normal
Overweight
Obese
Caucasian
Hispanic

Local or No
Metastasis
(N=863)
n (%)
Mean: 53.5
Median: 52.8
352 (40.8)
439 (50.9)
72 (8.3)
Mean: 27.4
Median: 26.5
18 (2.09)
320 (37.08)
281 (32.56)
244 (28.27)
452 (52.38)
230 (26.65)

Distant
Metastasis
(N=101)
n (%)
Mean: 53.1
Median: 51.3
43 (42.6)
42 (41.6)
16 (15.8)
Mean: 28.7
Median: 27.6
1 (0.99)
27 (26.73)
36 (35.64)
37 (36.63)
54 (53.47)
29 (28.71)

Mean: 53.5
Median: 52.6
395 (41.0)
481 (50.0)
88 (9.1)
Mean: 27.5
Median: 26.6
19 (1.97)
347 (36.00)
317 (32.88)
281 (29.15)
506 (52.49)
259 (26.87)

African American

46 (5.33)

6 (5.94)

52 (5.39)

Other
Managed
Medicare
Medicaid
Other

135 (15.64)
480 (55.62)
139 (16.11)
234 (27.11)
10 (1.16)

12 (11.88)
42 (41.58)
23 (22.77)
35 (34.65)
1 (0.99)

147 (15.25)
522 (54.15)
162 (16.80)
269 (27.90)
11 (1.14)

Group
--

Age at Diagnosis

Below 50
50-70
Above 70
--

BMI

Race

Insurance
1

Total
(N=964)
n (%)

Continued on next page
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Table 2 Continued: Personal and Socio-Economic Status Characteristics
Local or No
Distant
Metastasis
Metastasis
Variable
Group
(N=863)
(N=101)
n (%)
n (%)
College Degree
411 (47.62)
23 (22.77)
Education Level2
No College
339 (39.28)
50 (49.50)
Unknown
113 (13.09)
28 (27.72)
Student
8 (0.93)
2 (1.98)
Employment
Employed
391 (45.31)
37 (36.63)
Status
Other
464 (53.77)
62 (61.39)
Mean:
Mean:
$52,251.31
$48,066.07
Income
-Median:
Median:
$50,047.00
$42,108.00
2

Total
(N=964)
n (%)
434 (45.02)
389 (40.35)
141 (14.62)
10 (1.04)
428 (44.40)
526 (54.56)
Mean:
$51,820.80
Median:
$49,818.00

Italicized variables in Tables 2-4 were significant in the final model

The clinical variables were stage at diagnosis and disease group. The stage at diagnosis variable
was collapsed into stage I, II or III. Of these groups, stage I patients are the least advanced and
stage III patients are the most advanced. A disease group variable was created based on estrogen
receptor (ER) status, progesterone receptor (PR) status, and Her2Neu status. ER, PR and Her2
are markers on cancer cells that identify how a patient will respond to different therapies. A
patient was classified as triple-negative if ER is negative, PR is negative, and Her2Neu status is
negative or low positive. A patient was classified as Her2Neu-positive if Her2Neu status is high
positive or positive NOS, regardless of ER and PR status. A patient was classified as luminal A
if they did not fit in to any of the previously mentioned groups. Table 3 shows a summary of
these variables.
Table 3: Clinical Characteristics
Variable
Stage at
Diagnosis
Disease Group

Group
I
II
III
Triple-negative
Her2Neupositive
Luminal A

Local or No
Metastasis
(N=863)
n (%)
262 (30.36)
433 (50.17)
168 (19.47)
134 (15.53)

Distant
Metastasis
(N=101)
n (%)
15 (14.85)
42 (41.58)
44 (43.45)
33 (32.67)

277 (28.73)
475 (49.27)
212 (21.99)
167 (17.32)

170 (19.70)

34 (33.60)

204 (21.12)

559 (64.77)

34 (33.66)

593 (61.51)

Total
(N=964)
n (%)

The treatment variables included: definitive surgery group, radiation and/or chemotherapy
treatment group, and concordance to NCCN guidelines. Definitive surgery group was defined
as: breast conserving surgery, mastectomy, or no cancer directed surgery. The treatment group
variable was created to indicate whether a patient had only chemotherapy, only radiation, or
both. The concordance variable was created to indicate whether the patient received the
9

treatment they were recommended to receive by the NCCN guidelines. Each patient is placed on
as many guidelines as they are eligible for. The guidelines are different pathways that a patient
can be classified on based on their clinical characteristics. These guidelines can recommend
different modalities of treatment including chemotherapy, radiation therapy, and/or other
treatment. For this analysis, patients were could only be on a radiation and/or chemotherapy
guideline or no guideline because of the exclusions that were made. The concordance variable
used in this analysis indicates whether or not the patient followed the care of the given guideline
that they were on. Table 4 contains summaries for these clinical variables.
Originally, one concordance variable was created that considered both radiation and
chemotherapy together. The variable was first broken up into many specific categories for
combinations of chemotherapy and radiation concordance. However, during analysis, SAS gave
an error due to quasi-complete separation of the data points. The concordance variable was then
collapsed into groups for concordant chemotherapy and radiation, concordant radiation (not
considering whether or not the patient had a discordant chemotherapy or not on a chemotherapy
guideline), concordant chemotherapy (again, not considering discordant radiation or not on a
radiation guideline), and not concordant at all. Again, the concordance variable gave some
unusual results which were difficult to interpret. So the variable was then split into two
variables, one based on chemotherapy and one based on radiation therapy, to investigate where
the odd behavior was coming from. A concordance variable was defined for patients on a
radiation therapy guideline (yes, no, n/a for concordance) and another variable for patients on a
chemotherapy guideline (same categories). From these variables, the analysis was able to
pinpoint which therapy was significant, if any.
Table 4: Treatment Characteristics
Variable

Definitive
Surgery Group

Treatment Group

Chemotherapy
Concordance
Radiation
Concordance

Group
Breast
Conserving
Surgery (BCS)
Mastectomy
No Definitive
Surgery
Chemotherapy
Alone
Radiation Alone
Chemotherapy
and Radiation
Yes
No
N/A
Yes
No
N/A

Local or No
Metastasis
(N=863)
n (%)

Distant
Metastasis
(N=101)
n (%)

Total
(N=964)
n (%)

484 (56.08)

46 (45.54)

530 (54.98)

367 (42.53)

53 (52.48)

420 (43.57)

12 (1.39)

2 (1.98)

14 (1.45)

213 (24.68)

26 (25.74)

239 (24.79)

174 (20.16)

8 (7.92)

182 (18.88)

476 (55.06)

67 (66.34)

543 (56.33)

465 (53.88)
157 (18.19)
241 (27.93)
488 (56.55)
45 (5.21)
330 (38.24)

61 (60.40)
18 (17.82)
22 (21.78)
45 (44.55)
9 (8.91)
47 (46.53)

526 (54.56)
175 (18.15)
263 (27.28)
533 (55.29)
54 (5.60)
377 (39.11)
10

The concordance variable required creative programming in order to create the variable since the
sets of guideline and concordance variables had to be examined and combined to create one
variable. As previously described, concordance and guideline each had a set of four variables for
each patient. To create the chemotherapy and radiation concordance variables, arrays were setup for the guideline and concordance variables. In a do loop, each guideline was tested for type
of therapy recommended and the corresponding concordance was extracted. The concordance
variables were increased by one if the patient was concordant. For example:
do i=1 to 4;
if conc(i)='Yes' and (substr(guide(i),1,4)='invx' or
guide(i)='invtx1' or guide(i)='invtx1b' or guide(i)='invtx1c')
then RTConcord=rtconcord+1;
if conc(i)='Yes' and (substr(guide(i),1,4)='inva' or
guide(i)='invtx1' or guide(i)='invtx1b' or guide(i)='invtx1c' or
guide(i)='invtx1a' or guide(i)='invtx2')
then ChemoConcord=chemoconcord+1;
end;

After deciding when a patient was concordant, there had to be a way to break up not concordant
patients and the “not applicable” patients. At this point, patients either had a value of 1 if they
were concordant or 0 if they were not concordant or not applicable. These “N/A” patients
included those that were not evaluated for concordance or were put on a different guideline not
relevant to the given modality. This occurs when a patient does not have the clinical
characteristics specific to a guideline. In order to break up the groups, another do loop was
created to check the two sets of four variables. The loop would only start if the patient did not
have a “Yes” for either concordance variable. The following code was used to break up these
groups:
if (chemconcord=0 or rtconcord=0) and guide(1)~='Not evaluated for
concordance' then do i=1 to 4;
if conc(i)='No' and (substr(guide(i),1,4)='invx' or guide(i)='invtx1'
or guidei)='invtx1b'
or guide(i)='invtx1c')
then rtconcord=2;
if conc(i)='No' and (substr(guide(i),1,4)='inva' or guide(i)='invtx1'
or guide(i)='invtx1b'
or guide(i)='invtx1c' or guide(i)='invtx1a' or guide(i)='invtx2')
then chemconcord=2;
end;

After the do loop and testing for non-concordance, the concordance variables ended up with a
value of 1 if the patient was concordant, a value of 2 if the patient was not concordant, and a
value of 0 of the patient was not on a guideline.
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3. Analysis
Once the final analytic data set was created, PROC FREQ was run on categorical predictors and
PROC MEANS was run on continuous predictors to get a sense of the data and indicate any
missing values. These results are summarized in the three tables shown in the previous section.
In SAS, PROC LOGISTIC was used to run logistic regression models and investigate
relationship between the predictors of interest and the distant metastasis response variable. The
outcome modeled was distant metastases equal to yes, so the odds ratio interpretations are thus
predicting the odds of a patient getting distant metastasis. Since most of the predictors were
categorical, reference groups had to be assigned for each variable. These reference groups were
defined based on what clinically would be least likely to result in distant metastasis for ease of
interpretation of the results. This means that the groups of greatest interest (more likely to get
distant metastasis) would have a predictor coefficient in the model. For example, Stage “I” was
chosen as the reference group for the stage variable since Stage I patients are less advanced and
thus were predicted to be less likely to get a distant metastasis. In addition, “Luminal A” was
chosen as the reference for disease group, “College degree” was chosen as the reference for
education, and “Yes” was chosen as the reference group for the Concordance variables.
In addition to testing all the covariates, possible interactions were also considered. Instead of
relying on a stepwise regression to come up with interactions that might not make sense
clinically, meaningful interactions were established a priori and then tested in the model. First,
the clinically meaningful interactions were tested, such as age with treatment group, treatment
group and disease group, and various other combinations. However, all of the interactions tested
turned out to be insignificant. In the end, stepwise selection was used as a back-up in case any
significant interactions were missed, but still, none came up as significant and it was decided that
the effect of any of the predictors did not depend on other predictors.
Three models were considered: a saturated model with all covariates of interest, a significant
borderline model with all covariates that had a p-value <0.10, and a significant terms only model.
The saturated model included many insignificant variables and did not turn out to be a useful
model. From the saturated model, least significant variables were removed one at a time until all
variables fit within the significance level desired. The final significant model included one
socio-economic variable for education level, two clinical variables for disease group and stage,
and one treatment variable for chemotherapy concordance. The borderline model also included
the categorical age group variable and continuous BMI variable in addition to the significant
model predictors, however these variables did not add much more information to the model. The
significant model was used as the final model as reported in this paper.

3.1 Assumptions
One of the biggest advantages of logistic regression is that there are not as many restrictive
assumptions as in linear regression. The first assumption is that there is linearity between the
logits and explanatory variables. However, since all of the significant predictors in the final
model are categorical, this was not an assumption of concern in this analysis. Independent
observations are also needed, but since this data is from de-identified retrospective data
collected, this was not something that could be controlled for during this analysis. However, it is
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obvious that one patient getting a distant metastasis has nothing to do with another patient’s
experience with distant metastasis and there also is no reason to think that the patients have any
genetic relationships. Large sample size is ideal for logistic regression and this was not a
problem (with a final sample size of 964 patients) for this data set. Another assumption is no
multicollinearity between the explanatory variables, and no outliers. These two assumptions will
be addressed in the Diagnostics section of the paper. Otherwise, no assumptions were violated.

3.2 Results
The final model included the variables for disease group, chemotherapy concordance, stage at
diagnosis, and education level. Table 5 provides a summary of odds ratio estimates and
confidence intervals for each significant variable in the model.
Table 5: Significant Model Estimates
Variable

Overall P-Value

Disease Group

<0.0001

Chemotherapy
Concordance

0.0008

Stage at
Diagnosis

<0.0001

Education Level

<0.0001

Group
Luminal A
Her2Neu-positive
Triple-negative
Yes
No
N/A
I
II
III
College Degree
No College
Unknown

Odds Ratio
95% Confidence
Estimate
Interval
Reference
3.223
(1.884, 5.516)
3.881
(2.250, 6.694)
Reference
0.911
(0.492, 1.686)
0.317
(0.173, 0.583)
Reference
1.234
(0.650, 2.341)
5.406
(2.744, 10.650)
Reference
2.462
(1.435, 4.225)
4.810
(2.571, 8.999)

As seen in Table 5, the significance of the disease group variable provided an explanation to the
first research question of interest. Patients with triple-negative disease were estimated to be 3.88
times more likely to develop a distant metastasis than those with luminal A (95% CI 2.25 –
6.69). Similarly, patients in the Her2Neu-positive disease group were also associated with
higher odds of having distant metastasis than patients in the luminal A group (OR = 3.22 95% CI
1.88 – 5.52).
As previously mentioned, the concordance variable gave some unusual results. But, the
significance of the chemotherapy concordance provided some explanation for the second
research question relating to a patient’s treatment. Concordance was originally one variable that
considered both radiation and chemotherapy. Since this variable behaved unusually (with the
N/A patients less likely to get distant metastasis), the variable was broken down into two
variables, one for radiation concordance and one for chemotherapy concordance, to target where
this problem was coming from. The chemotherapy concordance turned out to be the culprit. The
radiation variable turned out not to be a predictor of distant recurrence and was not included in
the final model. As seen in Table 5, the “N/A” patients (those who were not evaluated for
concordance or not on a guideline) were associated with being significantly less likely to have
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distant metastasis than patients who were concordant for chemotherapy (OR = 0.32 95% CI 0.17
– 0.58). Patients who were not concordant were not significantly associated with developing
distant metastasis than those who were concordant.
Stage at diagnosis had one significantly different group, which were the Stage III patients. Stage
III patients were associated with 5.41 higher odds of having distant metastasis than Stage I
patients (95% CI 2.74 – 10.65), after considering the other variables in the model. Stage II
patients were not significantly more or less likely to have distant metastasis than Stage I patients.
Finally, education level was the only significant non-treatment or non-clinical variable. Patients
with no college education were 2.46 times more likely to develop distant metastasis than those
with a college education (95% CI 1.44 – 4.23), considering the other covariates in the model.
Similarly, patients with unknown education level also were estimated to have higher odds of
getting distant metastasis than patients with a college degree (OR = 4.81 95% CI 2.57 – 9.00).
Figure 1 provides a visual representation of the odds ratios for each level of the covariates. The
width of the band corresponds to the width of the 95% confidence interval.
Figure 1: Odds Ratios Plot

3.3 Diagnostics
In order to ensure the validity of the model and to solidify any conclusions, it is essential to
check model fit and other diagnostics. SAS was used to run a Hosmer-Lemeshow Goodness-ofFit Test. The result was a Chi-Square test statistic of 2.4116 with 8 degrees of freedom and a pvalue of 0.9657, which means that there is no evidence that this model is not a good fit to the
data. In addition, Deviance and Pearson Goodness-of-Fit Statistics for the logistic regression
residuals were tested. Deviance gave a value of 70.4679 with 68 degrees of freedom, which
gave a ratio (value/df) of 1.0363 and a p-value of 0.3951. Also, Pearson gave a value of 60.9382
with 68 degrees of freedom, which is a ratio of 0.8961 and p-value of 0.7157. Since the ratios
were close to 1, there is no indication of severe under- or over-dispersion. As there were no
dispersion issues, there does not appear to be evidence that the binomial assumption is not valid
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for this model. SAS also gives an R2 value of 0.2057. Although this value is not very
impressive, this is sometimes the case with real patient based data and is not something to be
very concerned with in this analysis.
Multicollinearity among the predictors was tested using PROC CORR with the Spearman
correlation coefficients, as the predictors were categorical variables. Table 6 shows a summary
of these results. Some of the covariates have significant correlations, however this is usually the
case with large sample sizes. Since none of the correlations appear to be very large and standard
errors of the estimates are low, multicollinearity does not seem to be an issue in this model.
Table 6: Spearman Correlation Coefficients
rs
Stage at
Disease Group
Prob>|rs|
Diagnosis
-0.114
Disease Group
1.000
0.0004
Stage at
-0.114
1.000
Diagnosis
0.0004
-0.035
0.087
Education Level
0.2768
0.0069
Chemotherapy
0.126
-0.282
Concordance
<0.0001
<0.0001

Education Level
-0.035
0.2768
0.087
0.0069
1.000
0.024
0.4482

Chemotherapy
Concordance
0.126
<0.0001
-0.282
<0.0001
0.024
0.4482
1.000

Finally, unusual observations and case-influence diagnostics were investigated. Figure 2 shows
diagnostic plots for the model. The top two plots are residual plots. Note that the distinct
separation of the residuals is due to the different response groups. Distant metastasis patients
have the positive residuals, while the no metastasis patients have the negative residuals. If
anything, the residual plots show a distinct difference between the no distant metastasis patients
and the distant metastasis patients. These plots also show a random scatter of points and there is
no distinct curvature or pattern. In this case, Pearson residuals are equivalent to the standardized
Pearson residuals because of the large sample size. The Pearson and standardized Pearson
residuals were output to a new data set and compared to ensure that their values were equal. In
most cases, the values differed only after the first decimal place. It appears that many of the
residual values are high (>3.3), however this is not unusual for real life data. There were actually
only 21 observations out of the total 964 with a standardized Pearson residual > 3.3 out of 964
observations. These 21 observations were printed with their corresponding leverage values and
Cook’s distance to investigate possible high leverage or influence. None of these observations
had high leverage or influence, so these observations were not considered a problem. The
leverage and influence plots in Figure 2 also show that none of the observations had very high
leverage or influence. These measure potential effects of the observations on the model results.
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Figure 2: Diagnostic Plots

Those without distant metastasis tend to have smaller residuals and leverage, which indicates
these patients probably have more traits in common. On the other hand, the distant metastasis
patients have many more outliers, higher leverage, and residuals, which might indicate that these
patients are more unique and have many different characteristics. This observation just
reinforces the unpredictability of cancer and why it is so difficult to make predictions about the
disease. In addition, these disparities might have come about because of the sample size
differences between the groups. The local or no metastasis group had 863 observations and the
distant metastasis group had 101 observations. Thus it makes sense that since the distant
metastasis patients are so different from their counterparts, they would have higher leverage
values. The sample size disparity also makes sense because distant metastasis is much less
common for the average breast cancer patient. A study from the Journal of Clinical Oncology
reported that a small percentage (31 out of 226, 13.7%) of breast cancer patients with pathologic
complete response after chemotherapy experience distant metastasis. This is similar to the
results in this study, with 101 out of 964 (10.5%) patients experiencing distant metastasis.
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4. Conclusions
The last part of the analysis for this project includes interpretation and explanations for the
model results. From the maximum likelihood estimates, a function for the log-odds of
developing distant metastasis can be calculated:
where each variable is 1 if the patient is in that group or 0 if the patient is not. The variables are:
x1: Disease group “Her2Neu-positive”
x2: Disease group “Triple-negative”
x3: Stage “II”
x4: Stage “III”
x5: Education level “No college”
x6: Education level “Unknown”
x7: Chemotherapy concordance “N/A”
x8: Chemotherapy concordance “No”
The log-odds of event occurrence is difficult to interpret, so the log-odds function can be
converted into an odds function using the formula:
. Finally, the probability
function is then given by
analysis:

. We end up with the final probability function for this
. This function models

the probability of a patient developing a distant metastasis, given the characteristic values of the
patient.
As displayed in Figure 3, triple-negative patients have a consistently higher probability of
developing distant metastasis, while luminal A patients are much less likely to have distant
metastasis. Triple-negative patients have negative estrogen receptors, progesterone receptors,
and Her2Neu, which means the growth of the cancer is not supported by the hormones estrogen
and progesterone, nor by the presence of too many Her2Neu receptors. As a result, triplenegative breast cancer does not respond to hormonal therapy or other targeted therapies. Since
triple-negative patients require unusual treatment courses, it makes sense that these patients
would be more likely to develop a distant metastasis because they are so different from other
patients. On the other hand, luminal A patients are much more common and easier to treat.
Patients in the luminal A group have markers on their cells to indicate that they will respond well
the hormone therapies that are common for breast cancer treatment. These patients generally
respond better to treatment and are therefore less likely to develop distant metastasis.
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Figure 3: Probability Plot by Disease Group

Figure 4 illustrates the probability of having distant metastasis for patients in the different
chemotherapy concordance groups. Patients in the N/A group were consistently less likely to
have distant metastasis. This result is unusual and unexpected, which makes it somewhat
difficult to interpret. Patients in this group cannot be placed on a guideline due to some
unknown clinical characteristics so this may just be a chance observation on a group of patients
with mixed clinical characteristics. The rates of concordance groupings were evaluated to
compare the no metastasis patients with the distant metastasis patients across all the variable
groupings in an attempt to discover why these patients received such an unusual result. No
apparent differences were discovered to explain any special characteristics that the N/A patients
might have. However, this was expected since there were also no significant interactions. The
N/A patients cannot be placed on a guideline due to some missing clinical characteristic or some
other unknown reason, so it is difficult to explain any reasons these patients might be less likely
to have a distant metastasis. Further research is necessary to understand why this result was
obtained and to investigate whether these results were observed only for this subset of patients.
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Figure 4: Probability Plot by Chemotherapy Concordance

Figure 5 shows probability differences for the stage groups. It is clear that Stage III patients are
much more likely to develop distant metastasis. Stage III patients are more advanced in the
disease at diagnosis than Stage I patients. Stage III patients are more advanced because they
have larger tumors and cancer in more lymph nodes (which allows cancer to spread), but the
cancer has not actually metastasized yet. Thus, because Stage III patients are further along they
are usually harder to treat and have a higher probability of developing distant metastasis.
Figure 5: Probability Plot by Stage

As discussed previously, it was found that patients with a college degree were less likely to
develop a distant metastasis. This result could be due to patients with a higher education level
being more informed and more likely to get the treatments they need. Patients with less
education may go untreated for longer or not receive the treatment they need at all. It is also
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possible that patients with more education have better jobs and might have better access to
healthcare. There are many explanations for this result, but further research could be used to
pinpoint the exact reasons. Figure 6 provides a visual representation of these probability
differences for education.
Figure 6: Probability Plot by Education Level

20

5. Limitations
This analysis had several limitations. The first limitation was that recurrence data is difficult to
come by in breast cancer patients. These patients have to be followed and observed for long
periods of time in order to find any recurrence of the disease. These patients survive long after
their initial diagnosis so there is a chance patients will drop out of the study for one reason or
another, or even expire due to another non-breast cancer related cause and before experiencing
any recurrence. For this reason, records on distant metastasis can be incomplete and difficult to
obtain.
In addition, these patients are from a limited sample from the City of Hope. If there were a way
to access all patient records, including care at outside clinics, to be sure distant metastasis had or
had not occurred, this would provide an ideal analysis. However, this is certainly unrealistic and
a possible limitation of this study.
Another limitation of this study is lack of knowledge of clinical meaning and in depth knowledge
of the disease. It would be ideal to work with a physician to help identify possible predictors,
because of their knowledge about what contributes to the disease. Additionally, a physician
could provide clinical opinions on the analysis and results. This would allow for better
interpretation and would significantly strengthen the results.
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6. Suggestions for further research
Originally, the analysis included an additional research question about whether treatment group
or disease group is associated with “quicker” time to metastasis. As proposed, this analysis
would have included only patients that actually experienced a distant metastasis and investigated
a regression model, which would have included an age at metastasis variable and a time to
metastasis variable. Since the data set for this analysis only included 101 patients with distant
metastasis, the sample size was not sufficient to conduct such an analysis. This resulted in a
more in-depth analysis for the first research question. However, it would be interesting to
conduct analysis on this secondary question if provided a larger sample size. This could be done
using a disease-free survival analysis to look at time to recurrence. However, the limited followup information as noted in the limitations section makes this analysis far beyond the scope of this
research paper.
Another interesting question is what factors influence where the breast cancer spreads? The
National Cancer Institute states that the main sites of breast cancer metastasis are the lungs, liver,
and bones. It makes sense that cancer would spread to the closest areas to the breast, but perhaps
there are other reasons for recurrence patterns. An analysis could be done on patient
characteristics and clinical variables and with different metastatic sites to see if there is any
relation between certain these characteristics and their primary metastatic sites. A larger data set
would be necessary for this analysis as well.
In addition, much research has been done on gene expression and genetics, and it would be
interesting to do further research in this area. The National Foundation for Cancer Research has
done research on which genes suppress metastasis and how their metastasis-suppressing function
is regulated, but a more complete understanding has yet to be discovered. This provides another
question to be analyzed: whether risk for getting distant metastasis is related to genetics in any
way. However, the genetic testing data in this database was very limited.
Research is key to developing new treatments and understandings of this disease. Continued
investigation of these research ideas, in addition to other important questions, is essential to
understanding cancer and working towards preventing and treating it effectively.
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8. Appendix
The following SAS code was used to carry out this analysis:
(Please note that the data for this analysis is confidential and is on file with Rebecca Ottesen)
**create libraries for derived and raw data;
libname ddata 'G:\Senior Project\sasdata\derived';
libname rawdata 'G:\Senior Project\sasdata\raw';
**tell SAS where to look for format catalogs;
option fmtsearch=(ddata.ddformats rawdata.formats);
**Read in Patient Characteristics derived data set;
data patchar; set ddata.patient_characteristics (drop=cid)
**delete all patients without Follow-up for Radiation Therapy Analyses;
if FUrt=1;
run;
**Read in Clinical Characteristics derived data set;
data clnchar; set ddata.clinical_characteristics (drop=cid);
**Keep only stage I-III patients;
if finalstg>=23 and finalstg<=27.5;
run;
**Read in Adjuvant Drug Therapy derived data set: Flags;
data adjtreat; set ddata.adjuvant_drug_therapy (drop=cid);
**Create flags indicating if a patient received chemo
if adjtxgroup=-99 then delete;
else if adjtxgroup in(1,2,6,7) then chemflag=1
else chemflag=0;
run;
**Read in Metastasis Patient Characteristics derived data set;
data mets; set ddata.mets_patient_characteristics (drop=cid);
run;
**Read in Surgical Information derived data set;
data surginf; set ddata.surgical_information (drop=cid);
run;
**Read in Concordance derived data set;
data concord; set ddata.concordance_status (drop=cid);
run;
**Transpose concordance data to get concordance,guideline,version,nreason
**rows for each patient;
proc transpose data=concord out=trconcord;
var concordance guideline version nreason;
by pid dxid tumorid;
run;
**Merge data with itself to get one record per patient;
data Mconcord;
merge trconcord (where=(_NAME_='concordance')
keep=pid dxid tumorid _NAME_ COL1-COL4
rename=(COL1=Concordance1) rename=(COL2=Concordance2)
rename=(COL3=Concordance3) rename=(COL4=Concordance4))
trconcord (where=(_NAME_='guideline')
keep=pid dxid tumorid _NAME_ col1-col4
rename=(COL1=Guideline1) rename=(COL2=Guideline2)
rename=(COL3=Guideline3) rename=(COL4=Guideline4))
trconcord (where=(_NAME_='version')
keep=pid dxid tumorid _NAME_ col1-col4
rename=(COL1=Version1) rename=(COL2=Version2)
rename=(COL3=Version3) rename=(COL4=Version4))
trconcord (where=(_NAME_='Nreason')
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keep=pid dxid tumorid _NAME_ col1-col4
rename=(COL1=Reason1) rename=(COL2=Reason2)
rename=(COL3=Reason3) rename=(COL4=Reason4));
by pid dxid tumorid;
run;
**Read in Metsites raw data set;
data metsite; set rawdata.metastatic_sites (drop=cid studyid)
if initial=0 and ((site in(5,6,7,8,9,10,11,12,13,15,17,18,19,20))
or (site=16 and sitedt<mdy(1,1,2003)))
then DistMet=3; **Distant Met;
else if site~=. then DistMet=2; **Local Met;
run;
**Read in Study Accession raw data set;
data stdyacc; set rawdata.study_accession (drop=cid studyid);
run;
**Create format for new insurance variable, store in ddformats catalog;
proc format library=ddata.ddformats;
value newins
.='Missing'
-1='Unknown'
0='Other'
1='Managed'
2='Indemnity'
4='Medicaid/Indigent'
5='Medicare alone'
5.5='Medicare + Supp'
5.75='Medicare + Managed'
6='Self-Pay';
run;
**Read in Insurance raw data set;
data insurance; set rawdata.insurance (drop=cid studyid);
if assessid=0; **keep only first record of insurance;
*** reprogram insurance; * per MH grid 043003;
if ins1type=2 or ins2type=2 then do;
if ins1type~=5 and ins2type~=5 then newinsur=2;
else if ins1type=5 or ins2type=5 then newinsur=5.5;
end;
else if ins1type=1 or ins2type=1 then do;
if ins1type not in(4,5) and ins2type not in(4,5) then
newinsur=1;
else if ins1type=5 or ins2type=5 then newinsur=5.75;
* medicare+managed;
else if ins1type=4 or ins2type=4 then newinsur=4;
end;
else if ins1type in(4,7) or ins2type in(4,7) then do;
if ins1type~=5 and ins2type~=5 then newinsur=4;
else if ins1type=5 or ins2type=5 then newinsur=5.5;
end;
else if ins1type=6 or ins2type=6 then do;
if ins1type~=5 and ins2type~=5 then newinsur=6;
else if ins1type=5 or ins2type=5 then newinsur=5.5;
end;
else if ins1type in(0,3,8,9,10,11) or ins2type in(0,8,3,9,10,11)
then do;
if ins1type~=5 and ins2type~=5 then newinsur=0;
else if ins1type=5 or ins2type=5 then newinsur=5.5;
end;
else if (ins1type in(-1) and ins2type in(-1,.)) or
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(ins1type in(-1,.) and ins2type in(-1)) then newinsur=-1;
else if ins1type=5 and ins2type in(0,5) then newinsur=5.5;
else if ins1type=5 and ins2type in(-1,.) then newinsur=5;
else if ins1type in(-1,.) and ins2type=5 then newinsur=5;
else if ins1type=. and ins2type=. then newinsur=.;
format newinsur newins.;
run;
**Read in Solid Tumor Stage raw data set;
data ststge; set rawdata.solid_tumor_stage (drop=cid studyid);
run;
**Read in raw Treatment data set where txcat=10(radiation) and indication
**in(1,2,3,4);
data treat; set rawdata.treatment (drop=cid studyid);
if txcat=10;
where indication in(1,2,4);
run;
**Merge data by pid dxid and tumorid;
data merge1;
merge clnchar (in=a) ststge surginf Mconcord;
by pid dxid tumorid;
if a=1 then output;
**only keeps narrowed down records from derived data (one record
**per patient);
run;
**Merge data by pid and dxid;
data merge2;
merge merge1 (in=a) treat adjtreat mets metsite;
by pid dxid;
if site=. then DistMet=1; **define no met;
if a=1 and side=laterality then do;
**flag patients as having radiation if side=laterality
rtflag=1;
output;
end;
else if a=1 then do;
**otherwise keep narrowed records and flag no radiation
rtflag=0;
output;
end;
run;
**sort to pick distant sites trumping other sites;
proc sort data=merge2;
by pid dxid distmet;
run;
**overwrite merge 2 to narrow down one row per patient by keeping last
**diagnosis record;
data merge2; set merge2;
by pid dxid distmet;
if last.dxid=1;
run;
**Merge data by pid;
data mergelast;
merge patchar (in=a) merge2 (in=b) stdyacc insurance;
by pid;
if a=1 and b=1 then output;
**only keeps narrowed down records from derived data;
run;
**Check to see if there is more than one of the same value for a variable;
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proc freq data=mergelast noprint;
table pid / out=count;
run;
**print pid's with repeats;
proc print;
where count>1;
run;
**Define formats, save to derived data format catalog;
proc format library=ddata.ddformats;
**Disease Groups format;
value tripneg
3='TripNeg'
2='Her2'
1='LumA';
**Treatment Groups format;
value treatgrp
1='RT alone'
2='RT+Chemo'
3='Chemo alone';
**Distant Met Definition format;
value dist
1='Distant Metastasis'
0='Local or no met';
**BMI group format;
value bmi
1='Underweight'
2='Normal'
3='Overweight'
4='Obese';
**RT/Chemo Concordance variable format;
value rtchconc
3='N/A'
1='Yes'
2='No';
**Age group format;
value age
1='Below 50'
2='50-70'
3='Above 70';
**Stage variable format;
value stage
1='I'
2='II'
3='III';
**Race variable format;
value rce
1='Caucasian'
2='Hispanic'
3='African American'
4='Other';
**Education variable format;
value edu
2='Col'
1='NoCol'
3='Unkn';
**Employment variable format;
value emp
1='Employed'
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2='Student'
3='Other';
**Insurance variable format;
value insur
1='Managed'
2='Medicare'
3='Medicaid'
4='Other';
run;
**Create analysis data set from final data set;
data analysis exclude; set mergelast
(keep=pid dxid tumorid her2neu metage diagage distmet finalstg dsgroup
racecomp p053001 edustat empstatdx initial ins1type ins2type newinsur
site furt laterality adjtxgroup indication side heightpres weightpres
chemflag rtflag tmarker1 tmarker2 concordance: guideline:);
**create disease groups;
if tmarker1 in(.,-1) or tmarker2 in(.,-1) or Her2neu in(.,-1)
then delete;
else if tmarker1=0 and tmarker2=0 and (her2neu in(1,2)) then
DiseaseGrp=3;
else if her2neu in(3,4) then DiseaseGrp=2;
else DiseaseGrp=1;
**redifine distmet and combine local/no met for logistic regression;
if distmet=3 then distmet=1;
else if distmet=2 or distmet=1 then distmet=0;
**create BMI variable;
if heightpres~=-1 then do;
heightM=heightpres/100;
BMI=weightpres/(heightM**2);
end;
**create BMI groups;
if BMI<18.5 then BMIGrp=1;
else if BMI>=18.5 and BMI<25 then BMIGrp=2;
else if BMI>=25 and BMI<30 then BMIGrp=3;
else if BMI>=30 then BMIGrp=4;
**create variables to test for linearity in the logit;
linage=diagage*log(diagage);
if p053001>=0 then lininc=p053001*log(p053001);
if bmi~=. then linbmi=bmi*log(bmi);
**Define concordance variable;
array conc (4) concordance:;
array guide (4) guideline:;
RTConcord=0;
ChemoConcord=0;
do i=1 to 4;
if conc(i)='Yes' and (substr(guide(i),1,4)='invx' or
guide(i)='invtx1' or guide(i)='invtx1b' or
guide(i)='invtx1c') then RTConcord=rtconcord+1;
if conc(i)='Yes' and (substr(guide(i),1,4)='inva' or
guide(i)='invtx1' or guide(i)='invtx1b' or
guide(i)='invtx1c' or guide(i)='invtx1a' or
guide(i)='invtx2') then ChemoConcord=chemoconcord+1;
end;
**Break down no guideline/not on inva,invx guideline and not concord;
if (chemoconcord=0 or rtconcord=0) and guide(1)~='Not evaluated
for concordance' then do i=1 to 4;
if conc(i)='No' and (substr(guide(i),1,4)='invx' or
guide(i)='invtx1' or guide(i)='invtx1b' or
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guide(i)='invtx1c') then rtconcord=2;
if conc(i)='No' and (substr(guide(i),1,4)='inva' or
guide(i)='invtx1' or guide(i)='invtx1b' or
guide(i)='invtx1c' or guide(i)='invtx1a' or
guide(i)='invtx2') then chemoconcord=2;
end;
if chemoconcord=0 then chemoconcord=3;
if rtconcord=0 then rtconcord=3;
**Create groupings for Age variable;
if diagage<50 then AgeGroup=1;
else if diagage>=50 and diagage<=70 then AgeGroup=2;
else AgeGroup=3;
**Collapse stages into I,II,III only;
if finalstg>=23 and finalstg<=23.2 then Stage=1;
else if finalstg>=23.5 and finalstg<=25 then Stage=2;
else if finalstg>=25.5 and finalstg<=27.5 then Stage=3;
**Collapse race into Caucasian, Hispanic, African American or other;
if racecomp=1 then Race=1;
else if racecomp in(2,11,8,6,4) then Race=2;
else if racecomp=3 then Race=3;
else Race=4;
**Collapse education variable into College, no college, unknown;
if edustat in(5,6,7) then Education=2;
else if edustat in(1,2,3,4) then Education=1;
else Education=3;
**Collapse employment variable into employed, student, other;
if empstatdx in(1,2,5) then Employment=1;
else if empstatdx in(3,4) then Employment=2;
else Employment=3;
**Collapse insurance variable;
if newinsur=1 then Insurance=1;
else if newinsur in(5,5.5,5.75) then Insurance=2;
else if newinsur=4 then Insurance=3;
else Insurance=4;
**create treatment groups and output to analysis/exclusions data sets;
if chemflag=1 and rtflag=1 then do;
TreatGroup=2;
output analysis;
end;
else if rtflag=1 then do;
TreatGroup=1;
output analysis;
end;
else if chemflag=1 then do;
TreatGroup=3;
output analysis;
end;
**create exclusions output to check;
else output exclude;
**create significant variable labels;
label DiseaseGrp="Disease Group" distmet="Distant Metastasis"
chemoconcord="Chemotherapy Concordance"
Stage="Stage at Diagnosis" Education="Education Level";
**format variables
format diseasegrp tripneg. distmet dist. bmigrp bmi. Rtconcord
rtchconc. chemoconcord rtchconc. agegroup age. stage stage.
race rce. education edu. employment emp. insurance insur.
treatgroup treatgrp.;
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**only keep variables of interest for analysis
keep pid distmet diagage p053001 bmi bmigrp agegroup treatgroup
diseasegrp stage dsgroup race education employment
insurance rtconcord chemoconcord; **linbmi linage lininc ;
run;
**Run proc freq on categorical variables;
proc freq data=analysis;
tables distmet diseasegrp*distmet stage*distmet education*distmet
chemoconcord*distmet agegroup*distmet bmigrp*distmet
treatgroup*distmet dsgroup*distmet race*distmet
employment*distmet insurance*distmet rtconcord*distmet /
norow nopercent;
run;
**Run logistic regression analysis;
**Q: Are triple negs (TN) or treatment group (TG) associated with having
**distant metastasis?;
**also account/control for stage, age at diagnosis, and other socio-economic
**status variables;
ods graphics on;
proc logistic data=analysis plots=all;
class distmet (ref='Local or no met') diseasegrp (ref='LumA')
stage(ref='I') education (ref='Col')
chemoconcord (ref='Yes') / param=ref;
model distmet = diseasegrp stage education chemoconcord
/ lackfit aggregate scale=n rsquare stb iplots clodds=pl;
label diseasegrp='Disease Group' stage='Stage at
Diagnosis'
education='Education Level' chemoconcord='Chemotherapy
Concordance';
run;
ods graphics off;
**logistic regression for creating effects plots;
ods graphics on;
proc logistic data=analysis plots(only)=effect(sliceby=chemoconcord
connect);
*sliceby=diseasegrp sliceby=stage sliceby=education;
*sliceby=chemoconcord ;
class distmet (ref='Local or no met') diseasegrp stage
education
chemoconcord/ param=ref;
model distmet = diseasegrp stage education chemoconcord;
run;
ods graphics off;
**Genmod procedure for residuals;
ods graphics on;
proc genmod data=analysis plots=(stdreschi reschi leverage dobs);
class distmet (ref='Local or no met') diseasegrp (ref='LumA')
stage (ref='I') education (ref='Col') chemoconcord
(ref='Yes') / param=ref;
model distmet = diseasegrp stage education chemoconcord /
link=logit dist=bin;
output out=resids reschi=pearson stdreschi=stdpearson
leverage=lev cookd=infl;
run;
ods graphics off;
**Print observations with high residuals
proc print data=resids;
var pid distmet pearson stdpearson lev infl;
where stdpearson>3.3;
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run;
**Check for multicollinearity of predictors;
ods graphics on;
proc corr data=analysis spearman;
var diseasegrp stage education chemoconcord;
run;
ods graphics off;
**Investigate possible reasons patients not on a NCCN guideline are less
**likely to develop a distant met;
proc freq data=analysis;
where distmet=1; *where distmet=0;
tables chemoconcord diseasegrp*chemoconcord stage*chemoconcord
education*chemoconcord;
run;
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